New cell therapy aims to mop up lingering lymphoma
NCT ID NCT07006012
First seen Apr 16, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This early study tests a new cell therapy called RGL-305 in 12 lymphoma patients who still have traces of cancer after standard treatment. The therapy is given through an IV over several cycles. The main goal is to check if it is safe and how the cells behave in the body, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA PATIENTS WITH COMPLETE RESPONSE (CR) OR PARTIAL RESPONSE (PR) AFTER STANDARD TREATMENT HAD A POSITIVE MINIMAL RESIDUAL LESION (MRD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RGL-305 (a cell therapy given intravenously)
What this could lead to
If it works, this could point toward a new way to eliminate remaining cancer cells in lymphoma patients who still have minimal disease after standard treatment.
What could go wrong
This is a very early, small study with only 12 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and cell therapies can cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.